Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.
暂无分享,去创建一个
Xuesong Yu | Gary Li | Hongmei Gao | Marcella Sarzotti-Kelsoe | Daniel A Ozaki | David C Montefiori | Yunda Huang | Kelli M Greene | D. Montefiori | P. Gilbert | Yunda Huang | H. Gao | Christopher A Todd | Daniel A. Ozaki | Christopher A. Todd | Xuesong Yu | B. Wood | Peter Gilbert | Maggie Wang | Ronald Brown | Blake Wood | M Patricia D'Souza | M. D’Souza | M. Sarzotti-Kelsoe | Gary Li | Maggie Wang | K. Greene | Ronald Brown | Hongmei Gao
[1] J. Bradac,et al. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.
[2] Feng Gao,et al. Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa , 2006, Journal of Virology.
[3] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[4] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[5] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[6] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[7] Q. Sattentau,et al. International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II , 2009, PloS one.
[8] Alternate members,et al. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise , 2010, Nature Medicine.
[9] H. Fleury,et al. Establishment of a national network of validated and qualified laboratories for neutralizing anti-vaccinia antibodies titration. , 2005, Biologicals (Print).
[10] Marcella Sarzotti-Kelsoe,et al. Evaluation and Recommendations on Good Clinical Laboratory Practice Guidelines for Phase I–III Clinical Trials , 2009, PLoS medicine.
[11] G. Enterprise,et al. The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan , 2005, PLoS medicine.
[12] J. Kappes,et al. Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120 , 2000, Journal of Virology.
[13] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[14] H. Liao,et al. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. , 2010, AIDS research and human retroviruses.
[15] D. Dimitrov,et al. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. , 2006, Biochemical and biophysical research communications.
[16] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[17] Y. Takeuchi,et al. Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research , 2008, Journal of Virology.